학술논문
Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group.
Document Type
Article
Author
Caminati, Marco; Fassio, Angelo; Alberici, Federico; Baldini, Chiara; Bello, Federica; Cameli, Paolo; Conticini, Edoardo; Cottin, Vincent; Crimi, Claudia; Dagna, Lorenzo; Delvino, Paolo; Deroux, Alban; Duran, Emine; Espigol‐Frigole, Georgina; Karadag, Omer; Maule, Matteo; Moiseev, Sergey; Monti, Sara; Moroni, Luca; Padoan, Roberto
Source
Subject
*CHURG-Strauss syndrome
*ASTHMATICS
*MONOCLONAL antibodies
*INFLAMMATION
*PEARSON correlation (Statistics)
*WHEEZE
*
*
*
*
*
Language
ISSN
0105-4538
Abstract
This article examines the occurrence of eosinophilic granulomatosis with polyangiitis (EGPA) in patients with severe asthma who are being treated with anti-T2 monoclonal antibodies (mAbs). The study involved 30 EGPA patients from different countries who developed the disease while on anti-T2 therapy for severe asthma. The patients were receiving various mAbs, such as omalizumab, benralizumab, mepolizumab, dupilumab, and reslizumab. The article provides demographic, clinical, and treatment-related information about the study population. The findings suggest that EGPA can still develop in these patients despite the use of anti-T2 mAbs, and monitoring blood eosinophil count may be important in predicting disease progression. However, more research is needed to fully understand the relationship between EGPA and anti-T2 mAbs. [Extracted from the article]